|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Elan Corporation, plc (NYSE: ELN) today announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2009.
Medivation's stock price will rocket -- or crash -- when test results for its Alzheimer's drug Dimebon arrive sometime this spring.
Sales of the multiple sclerosis drug exceed $1 billion in 2009, but patient growth slows in fourth quarter.
Our senior biotech columnist offers his picks for the five biggest stock-moving events for 2010.
Elan is forced to cut high doses of its Alzheimer's drug ELND005 from a mid-stage study, while Seattle Genetics hooks up with a Japanese drug maker.
Stocks will move if any of these unexpected events come true.
Cramer says China still works for the stock, which has more room on the upside.
Cramer told viewers to look at this bull market as a relay race with one sector handing off the rally baton to another. Click for news from Jim Cramer.
European regulators update reports of serious brain infection tied to Tysabri.
Several small-cap stocks were moving on above-average volume during Friday's session
The Irish drugmaker swung to third-quarter net income of $52.3 million, or 11 cents a share, as sales of its Tysabri drug rose.
Why wait one week to discuss good breast cancer data?
A midstage study of Empatic demonstrates significant weight loss.
Nexavar study results not as strong as those posted last week.
Oculus turns to a director and large shareholder for Microcyn marketing help.
Proellex's future is in doubt after it received a letter from the FDA.
Tuesday's early headlines include reports that the government will begin to unload its 34% stake in Citigroup, a report that Chrysler will see a sharp decline in sales for September, and earnings from Best Buy and Kroger.
Elan said Johnson & Johnson will cut the value of a partnership deal to $885 million after Elan said it repaired a breach in its Tysabri agreement with Biogen Idec.
Monday's early headlines include a report Deutsche Telekom will launch a bid for Sprint Nextel, a separate report that Johnson & Johnson is looking to shave $100 million off its deal for Elan, and President Obama set to deliver remarks on the financial sector and regulation.
Johnson & Johnson is trying to lower the price of its deal with Irish biotech outfit Elan in the wake of a court ruling, according to a media report.
Investor conferences and phase III data on tap for post-Labor Day
The Irish drugmaker said it's committed to close a transaction with Johnson & Johnson as quickly as possible following a judge's ruling it has breached an agreement with Biogen for the marketing of Tysabri.
Allos Therapeutics' lymphoma drug will be approved and used.
Readers weigh in on Biocryst's flu drug, the forecast for Alzheimer's drugs, Allos' prognosis, and why AMAG's stock is getting pummeled.
Cramer says the company will be in a good position after an elimination of a glut of flash memory.
Cramer says money managers are feverishly buying on dips to get back into the market. Click for news from Jim Cramer.
The Irish drugmaker reported a narrower second-quarter loss as sales of multiple sclerosis drug Tysabri rose 30%.
Biogen Idec reported an 18% drop in adjusted second-quarter earnings, impacted by a one-time payment related to a recent drug-licensing deal, but sales of its multiple sclerosis drug Tysabri topped Wall Street expectations.
Readers weigh in on Chelsea's rheumatoid arthritis duo, Generex's diabetes spray, AMAG's stock dip, and Anadys' prospects.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.